Dicyclopentanone

Dicyclopentanone: A Reference Article on Identity, History, Proposed Mechanisms, and Evidence

1. Identity and Chemical Classification

Dicyclopentanone is the name applied in the dietary supplement trade to a class of organic cyclic ketone compounds sharing a dicyclopentanone core scaffold. The term as used commercially is not identical to a single, precisely defined chemical entity with one CAS registry number; rather, it refers to compound classes built upon fused or bis-cyclopentanone ring frameworks. The only compound directly and experimentally identified in peer-reviewed literature in connection with anabolic activity is 1,5-bis(1-carbethoxy-2-oxocyclopentyl-1)pentane, a derivative of the dicyclopentanone scaffold, which was the subject of a 1975 Soviet pharmacological study indexed on PubMed (PMID 1227920).

According to the NIH Office of Dietary Supplements' Dietary Supplement Label Database (DSLD), dicyclopentanone is categorized under the ingredient category of "Non-nutrient/non-botanical," and the database lists no associated scientific resources.

From a chemistry standpoint, the broader class of cyclopentanone-based compounds is characterized by five-membered carbocyclic ketone rings. Described in some commercial-chemistry literature, dicyclopentanone is characterized as an organic compound with the molecular formula C₁₀H₁₆O; a clear, colorless liquid with a mildly sweet odor; and classified as a cyclic ketone due to its five-membered cyclopentanone ring structure. However, these chemical descriptors must be interpreted with the caveat that this description does not necessarily match the specific ester derivatives marketed in sports nutrition formulations.

Dicyclopentanone is characterized as a synthetic compound and is not naturally occurring; it is industrially produced through various chemical processes, usually involving the hydrogenation of cyclic ketones. This is directly relevant to supplement marketing claims describing it as a "natural" ingredient, as no verified natural botanical or food source has been identified in the peer-reviewed literature.

Dicyclopentanone differs from many other commonly marketed muscle-building agents in that it is not a protein, creatine, or branched-chain amino acid (BCAA); instead, it is described as a compound with a rigid fused ring structure.

2. Common Forms and Supplement Preparations

In the dietary supplement context, dicyclopentanone does not appear to be marketed as an isolated, single-ingredient product but rather as one component of multi-ingredient anabolic or muscle-building formulations. In at least one commercially available product, it is described as being broken down into four different esters for the purpose of sustained release and effectiveness.

Product label information shows that in at least one multi-ingredient formulation, dicyclopentanone is included at a dose of 10 mg per serving within a broader "Non-Steroidal Anabolic Multi-Phase Stack" of 155 mg that also includes 6-Keto Diosgenin (100 mg) and its various ester forms. This labeling data, sourced from a supplement forum post referencing label copy, represents the only specific dosage figure attributable to an actual product. It cannot be confirmed as the dose used in any clinical study, because no clinical human studies on dicyclopentanone have been published.

One commercial product's label directions indicate taking one liquid capsule in the morning and one liquid capsule in the evening, for daily use in cycles, with a suggested cycle length of 12 weeks on and 4 weeks off. These dosing recommendations are provided by the manufacturer and are not derived from controlled clinical trial data.

In industrial and pharmaceutical chemistry, dicyclopentanone-class compounds are primarily used as chemical intermediates in the production of various pharmaceuticals, fragrances, and polymers, with primary application in pharmaceuticals and fragrances.

3. Traditional and Historical Use

There is no documented record of dicyclopentanone in any traditional herbal medicine system — including Ayurveda, Traditional Chinese Medicine (TCM), European phytotherapy, or any other ethnobotanical tradition — in any authoritative source accessible through peer-reviewed literature, WHO monographs, ESCOP, or national pharmacopeias. Because it is a synthetic compound with no identified naturally occurring source, a traditional use record in the conventional ethnobotanical sense does not exist.

The historical narrative most associated with dicyclopentanone in marketing contexts is that of Soviet-era sports pharmacology research. One manufacturer describes it specifically as "the secret anabolic compound from the former Soviet Union." This framing refers to the broader documented context of Soviet state-sponsored sports research programs, in which novel anabolic compounds were investigated for athletic performance enhancement. Documented Soviet-era research of this type was conducted at the Research Laboratory of Training Programming and Physiology of Sport Performance at the State Central Institute of Physical Culture in Moscow, with data from experiments conducted on human subjects (athletes) regarding androgenic-anabolic substances. However, there is no verified historical documentation specifically linking dicyclopentanone — as a named, distinct compound — to any state-sponsored Soviet distribution program; the "Soviet origin" framing as used in supplement marketing is a commercial claim, not one established by declassified or published historical documents that have been verified through independent scholarly sources.

The earliest verifiable scientific reference to a dicyclopentanone derivative in the context of anabolic biology is a 1975 study published in the Soviet journal Farmakologiya i Toksikologiya (Pharmacology and Toxicology), indexed on PubMed (PMID 1227920). This represents the limit of verified historical scientific engagement with the compound class.

4. Key Constituents and Proposed Mechanisms of Action

4.1 Chemical Structure and Receptor Interactions

Dicyclopentanone may serve as a core scaffold in the synthesis of synthetic androgens or prohormones, with its rigid, fused ring structure potentially affecting how the compound interacts with androgen receptors. This hypothesis is derived from structural chemistry reasoning, not from published receptor-binding assays or pharmacokinetic studies in humans.

The dicyclopentanone framework is hypothesized to improve the bioavailability or metabolic stability of a compound, potentially allowing it to last longer in the body or target certain tissues more effectively. Again, this is a theoretical proposition based on structural analogy rather than pharmacokinetic data from human studies.

4.2 Proposed Anabolic and Protein Synthesis Mechanisms

Dicyclopentanone is described in some supplement review contexts as a ketone that may support muscle development through mTOR (mechanistic target of rapamycin) activation, a pathway central to protein synthesis. There is no peer-reviewed human or clinical study that has tested mTOR activation specifically by dicyclopentanone; this mechanistic claim appears to be extrapolated from general knowledge of anabolic signaling rather than compound-specific research.

While the exact mechanism of action in relation to muscle growth is not fully understood, some researchers hypothesize that dicyclopentanone may influence protein synthesis and hormone regulation in the body. However, scientific studies on its effects in humans are limited, and much of the information circulating is based on anecdotal evidence and preliminary research.

4.3 Proposed Anti-Inflammatory Activity

Dicyclopentanone is described by at least one manufacturer as being believed to have anti-inflammatory properties, aiding in muscle recovery. No peer-reviewed study has specifically examined the anti-inflammatory activity of dicyclopentanone or its derivatives in humans, and no mechanisms for this proposed activity have been elucidated in the published scientific literature.

5. Scientific Evidence by Area of Use

5.1 Skeletal Muscle Anabolism — Animal Evidence

The sole identifiable peer-reviewed experimental study directly relevant to the anabolic effects of a dicyclopentanone derivative is a 1975 Soviet pharmacological investigation published in Farmakologiya i Toksikologiya (PubMed PMID 1227920). The study examined the compound 1,5-bis(1-carbethoxy-2-oxocyclopentyl-1)pentane, a derivative sharing the dicyclopentanone structural scaffold.

In this animal study, anabolic activity of 1,5-bis(1-carbethoxy-2-oxocyclopentyl-1)pentane at a dose of 1 mg per 100 g of body weight was manifested as accelerated growth of the animals, increased weight of the m. levator ani, and a rise in protein levels in the blood and skeletal muscle.

Because of the absence of androgenic properties in the substance under consideration, its anabolic coefficient was reported as twice as high in comparison with methylandrostendiol. This finding — if accurate — would be notable, since it implies dissociation between anabolic and androgenic activity. However, the study is more than five decades old, was conducted in animals (species not specified in the PubMed abstract), has not been independently replicated in any identifiable published study, and employed a specific ester derivative of the dicyclopentanone scaffold rather than dicyclopentanone itself.

Following hypophysectomy (surgical removal of the pituitary gland) in the animal model, a certain decline in the anabolic activity of the compound was observed, suggesting that at least part of the compound's anabolic effect was dependent on pituitary-mediated hormonal signaling rather than being entirely direct.

Assessment of evidence strength: The evidence for anabolic effects of dicyclopentanone derivatives is limited to a single, decades-old animal study conducted under Soviet-era conditions, published in a journal that may not have undergone modern peer-review standards, and involving a closely related but chemically distinct compound (a specific ester derivative, not the parent ketone). No replication, no dose–response characterization in humans, and no pharmacokinetic data in any species are available in the accessible published literature. This body of evidence is extremely weak and insufficient to establish efficacy in humans.

5.2 Skeletal Muscle Anabolism — Human/Clinical Evidence

Animal studies suggest that dicyclopentanone derivatives may help increase muscle mass by enhancing the body's ability to build muscle tissue, but more research is needed to fully understand its safety profile and potential benefits in humans.

No human clinical trial — randomized or otherwise — examining the effects of dicyclopentanone on muscle mass, strength, body composition, or any other outcome measure has been identified in PubMed, Cochrane, ClinicalTrials.gov, or any other accessible peer-reviewed or registered-trial database. The complete absence of human trial data means that no evidence-based efficacy conclusion can be drawn for any human health outcome.

5.3 Hormonal Effects

No peer-reviewed study documenting a specific hormonal effect of dicyclopentanone — whether on testosterone, growth hormone, luteinizing hormone, or any other endocrine parameter — in humans has been identified. Claims of hormonal modulation appear in marketing materials and supplement retailer content but are without verifiable experimental foundation in published human studies.

5.4 Anti-Inflammatory Effects

No peer-reviewed preclinical or clinical study specifically examining the anti-inflammatory properties of dicyclopentanone has been identified in any authoritative database. This proposed benefit is currently unsupported by any published experimental evidence.

6. Body Systems and Health Areas Associated with Dicyclopentanone

Based on the limited available literature and commercial claims, dicyclopentanone is associated — without verified clinical evidence — with the following body systems:

• Musculoskeletal system: Proposed promotion of skeletal muscle hypertrophy and increased muscle protein content, based on the single 1975 animal study.
• Endocrine system: Proposed interaction with androgen receptors and possible modulation of hormonal pathways; partially supported by the animal study's hypophysectomy findings but without human data.
• Immune/inflammatory system: Proposed anti-inflammatory activity supporting post-exercise recovery; currently without any peer-reviewed experimental support.

A 2023 peer-reviewed systematic review of ergogenic properties, safety, and regulatory status of ingredients in testosterone-boosting dietary supplements, published in a Taylor & Francis journal, found that dicyclopentanone was among the few ingredients "not found in any of the reviewed databases," meaning it was absent from standard ingredient reference tools used by regulatory and scientific bodies at the time of review.

7. Regulatory and Database Status

The NIH Office of Dietary Supplements' Dietary Supplement Label Database (DSLD) classifies dicyclopentanone as a "Non-nutrient/non-botanical" ingredient and lists no associated scientific resources under its entry.

The legal status of dicyclopentanone varies by country and is often in a regulatory gray area; in many jurisdictions, it is not explicitly banned but also not approved for human consumption or as a dietary supplement. This legal ambiguity can lead to quality control issues and potential contamination risks in products marketed as containing dicyclopentanone.

There is no entry for dicyclopentanone in the European Food Safety Authority (EFSA) Compendium of Botanicals, no WHO monograph, no ESCOP monograph, no German Commission E monograph, no USP entry, and no listing in the European Pharmacopoeia. It does not appear on the WADA Prohibited List as a specifically named substance (as of the 2023 Prohibited List).

No FDA Generally Recognized As Safe (GRAS) determination has been identified for dicyclopentanone or its supplement-relevant derivatives, and no New Dietary Ingredient (NDI) notification has been publicly confirmed for this substance. The NIH DSLD notes that manufacturers or distributors are responsible for label information, and that the FDA maintains lists of ingredients of concern and products that are adulterated or misbranded.

8. Dosage Forms and Reported Dosages

No clinical trials have established a human dosage range for dicyclopentanone. The only experimental dosage available in the peer-reviewed literature is from the 1975 Soviet animal study. In that study, anabolic activity was demonstrated at a dose of 1 mg per 100 g of body weight in animals. This cannot be directly extrapolated to a human equivalent dose without allometric scaling calculations and pharmacokinetic data that do not currently exist in the published literature.

At least one commercially available multi-ingredient supplement formulation lists dicyclopentanone at 10 mg per serving within a larger proprietary blend. This is a label-declared dosage, not a clinically validated or therapeutically established dose.

Manufacturer-recommended usage for one product containing dicyclopentanone is one liquid capsule in the morning and one liquid capsule in the evening. No dose-escalation, dose-response, or safety-threshold study has been published for any formulation containing dicyclopentanone.

9. Safety Considerations

9.1 Toxicological Data

No independently conducted, peer-reviewed toxicological study on dicyclopentanone or its supplement-relevant derivatives in humans or animals has been identified in accessible scientific databases beyond the 1975 anabolic activity study, which did not systematically characterize safety endpoints. Due to the lack of comprehensive clinical trials, the full range of potential side effects of dicyclopentanone and their severity is not well understood.

9.2 Regulatory Safety Status

No safety evaluation specific to dicyclopentanone has been published by the FDA, EFSA, or any national food safety authority identifiable through peer-reviewed sources. Because of its classification as a synthetic, non-botanical compound with no GRAS status, no NDI notification, and no inclusion in any pharmacopeia, the compound lacks the regulatory safety evaluation that many established dietary supplement ingredients carry.

9.3 Endocrine System Concerns

In the broader context of testosterone-booster category ingredients, researchers have noted that hypothetically, all cases of endocrine-active supplement use pose a possible risk of endocrine system dysregulation or imbalance. Given that dicyclopentanone's proposed mechanism involves interaction with androgen receptors and pituitary-dependent hormonal pathways (as suggested by the 1975 animal hypophysectomy data), theoretical endocrine risks exist, but have not been characterized in any peer-reviewed safety study.

9.4 Drug Interactions

No peer-reviewed study or authoritative pharmacokinetic analysis of dicyclopentanone interactions with pharmaceuticals has been identified. No interaction data with cytochrome P450 enzymes, hormone-modulating medications, corticosteroids, or other androgenic or anabolic agents is available in the published literature.

9.5 Product Quality and Adulteration Risks

In many jurisdictions, dicyclopentanone is not explicitly banned but also not approved for human consumption or as a dietary supplement, and this legal ambiguity can lead to quality control issues and potential contamination risks in products marketed as containing dicyclopentanone. Because dicyclopentanone is a synthetic compound produced through industrial chemical processes, the purity, identity, and actual content of supplement products claiming to contain it cannot be assumed without independent third-party testing.

10. Summary of Evidence Quality

Dicyclopentanone occupies an unusual position among dietary supplement ingredients: it is a synthetically produced cyclic ketone compound with a single identifiable peer-reviewed experimental study (an animal study from 1975 in the Soviet literature) providing any biological data relevant to its claimed uses. As noted in a 2023 peer-reviewed review of testosterone booster supplement ingredients, dicyclopentanone is among the ingredients not found in any of the standard reviewed scientific or regulatory databases. There are no human clinical trials, no systematic reviews, no regulatory monographs, no GRAS determination, and no pharmacopeial standards applicable to this ingredient. All claims of efficacy — including muscle anabolism, protein synthesis promotion, and anti-inflammatory activity — are currently unsubstantiated by human evidence and supported, at best, by a single decades-old animal study examining a closely related but chemically distinct ester derivative.

As noted in independent review, some ingredients found in testosterone-booster supplements are backed by low scientific evidence, primarily animal studies, and dicyclopentanone clearly falls into this category — and arguably represents an even more extreme case given the scarcity of even preclinical published data.

References

• [Anabolic activity of some dicyclopentanone derivatives] — PubMed (PMID 1227920), Farmakol Toksikol. 1975 Nov-Dec;38(6):713-5
• Dicyclopentanone Ingredient Entry — NIH Office of Dietary Supplements, Dietary Supplement Label Database (DSLD)
• Ergogenic properties, safety evaluation and regulations of selected ingredients in testosterone booster dietary supplements — Critical Reviews in Food Science and Nutrition (Taylor & Francis, 2023)
• Ergogenic properties, safety evaluation and regulations of selected ingredients in testosterone booster dietary supplements (ResearchGate PDF, 2023)
• NIH Dietary Supplement Label Database (DSLD) — Home
• NIH Office of Dietary Supplements — Dietary Supplement Label Database Information
• Nutrex ANABOL HARDCORE — Product Label and Ingredient Information
• Nutrex ANABOL RIPPED — Product Label and Ingredient Information